Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;134(4):1214-1217.
doi: 10.1016/j.bja.2024.12.024. Epub 2025 Jan 24.

Preoperative SGLT-2 inhibitor use and risk of adverse postoperative events: a single-centre retrospective observational study

Theresa Tenge  1 , Sebastian Roth  2 , Elena Ahrens  3 , Luca J Wachtendorf  3 , Béla-Simon Paschold  3 , Guanqing Chen  3 , René M'Pembele  2 , Detlef Kindgen-Milles  2 , Anastasia Katsiampoura  4 , Peter Kienbaum  2 , Giovanna Lurati Buse  2 , Maximilian S Schaefer  5
Affiliations

Preoperative SGLT-2 inhibitor use and risk of adverse postoperative events: a single-centre retrospective observational study

Theresa Tenge et al. Br J Anaesth. 2025 Apr.
No abstract available

Keywords: chronic kidney disease; diabetes mellitus; heart failure; ketoacidosis; perioperative outcome; sodium–glucose cotransporter-2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest MSS received funding for investigator-initiated studies from Merck & Co., which do not pertain to this manuscript. He received an unrestricted philanthropic grant from Jeffrey and Judith Buzen and is an associate editor for BMC Anesthesiology. He received honoraria for lectures from Fisher & Paykel Healthcare and Mindray Medical International Limited. The funders had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All other authors have no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 yrs, and no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. - PubMed
    1. Solomon S.D., McMurray J.J.V., Claggett B., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–1098. - PubMed
    1. McGuire D.K., Shih W.J., Cosentino F., et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148–158. - PMC - PubMed
    1. McDonagh T.A., Metra M., Adamo M., et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J 2024; 45: 53] Eur Heart J. 2023;44:3627–3639. - PubMed
    1. Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:e876–e894. - PubMed

LinkOut - more resources